An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Pulse Biosciences (NASDAQ: PLSE) will announce its financial results for Q1 2022 on May 11, 2022, after market close. A conference call will follow at 1:30 PM PT. Investors can join by dialing 1-877-704-4453 (domestic) or 1-201-389-0920 (international), or via a live webcast at investors.pulsebiosciences.com. The company is focused on innovative bioelectric medicine, leveraging its CellFX® System powered by Nano-Pulse Stimulation™ technology to enhance dermatologic treatments.
Positive
Scheduled Q1 2022 financial results release may indicate strategic growth.
Potential for increased investor interest due to upcoming conference call.
Negative
None.
HAYWARD, Calif.--(BUSINESS WIRE)--
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the first quarter of 2022 after market close on Wednesday, May 11, 2022. Company management will host a corresponding conference call beginning at 1:30pm PT.
Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology, such as the ability to nonthermally clear cells while sparing non-cellular tissue, to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. To learn more, please visit pulsebiosciences.com.
To stay informed about the CellFX System, please visit CellFX.com and sign up for updates.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
When will Pulse Biosciences report Q1 2022 financial results?
Pulse Biosciences will report its Q1 2022 financial results on May 11, 2022.
What time is the conference call for Pulse Biosciences Q1 financial results?
The conference call will take place at 1:30 PM PT on May 11, 2022.
How can I listen to Pulse Biosciences' conference call?
You can listen to the conference call by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers, or through the live webcast at investors.pulsebiosciences.com.
What is the focus of Pulse Biosciences?
Pulse Biosciences focuses on bioelectric medicine, particularly through its CellFX® System which utilizes Nano-Pulse Stimulation technology for dermatologic applications.
